Latest / Pharmacy Podcast Network / Discussions on the Current Election Landscape of the Pharmaceutical Industry | Cardinal Health™ Counter Talk™ Podcast
Transcript
- 0:06Speaker 1: You are listening to the Pharmacy Podcast Network.
- 0:16Speaker 2: The testimonials appearing in this podcast reflect individual experiences, and
- 0:19Speaker 2: individual results may vary. Cardinal health is not claimed, or
- 0:22Speaker 2: should the listener assume that any individual experience recounted in
- 0:25Speaker 2: this podcast is representative of what another consumer may experience.
- 0:35Speaker 2: The Cardinal Health counter Talk podcast and collaboration with Pharmacy
- 0:38Speaker 2: Podcast Network is for independent pharmacists to learn about the
- 0:41Speaker 2: state of the industry, innovative services and solutions, and the
- 0:44Speaker 2: future of pharmacy. Join me your host Jason colorI for
- 0:47Speaker 2: conversations with pharmacists, cardinal health leaders, and industry experts, sharing
- 0:52Speaker 2: best practices, discussing industry trends, and showcasing cardinal health products
- 0:56Speaker 2: and services. If you could subscribe to the Cardinal Health
- 0:58Speaker 2: counter Talk podcast on Spotify, Apple Podcasts, and wherever you
- 1:02Speaker 2: listen to your favorite podcasts. Hello everyone, and welcome back
- 1:05Speaker 2: to the Cardinal Health counter Talk podcast.
- 1:07Speaker 3: I'm your host Jason Colorian.
- 1:08Speaker 4: Today we will be providing an update on everything happening
- 1:11Speaker 4: from a legislative standpoint in the world of pharmacy, What
- 1:15Speaker 4: to expect as we get towards the end of the year.
- 1:17Speaker 4: The upcoming election, PBM reform, and more so, here with
- 1:20Speaker 4: me to provide all that great information. Our special guests
- 1:23Speaker 4: from the Cardinal Health Government Relations team, our VP of
- 1:26Speaker 4: government Relations and familiar voice to the podcast, Jeric and
- 1:29Speaker 4: Mathis and joining her our director of government Relations, Brian Lowe.
- 1:32Speaker 4: So excited for today's episode. Guys, welcome to the show,
- 1:35Speaker 4: Jeric and Brian.
- 1:36Speaker 1: Thanks for having us, Thank you for having us.
- 1:38Speaker 4: Now, Jerica, you've been on here before, Brian, this is
- 1:40Speaker 4: your first time, correct, sure is?
- 1:42Speaker 3: I haven't.
- 1:42Speaker 4: I haven't seen your beautiful face here on the podcast
- 1:44Speaker 4: quite yet. So let's dive right into it. As we
- 1:48Speaker 4: move towards the end of the year, which has been
- 1:49Speaker 4: a busy twenty twenty four from a legislative standpoint in pharmacy,
- 1:53Speaker 4: we have the election coming up as well. What do
- 1:56Speaker 4: we anticipate happening, if anything here at the conclusion of
- 1:59Speaker 4: twenty twenty four.
- 2:00Speaker 5: I start off with you, Jerica, Yeah, absolutely, Just as
- 2:02Speaker 5: you've mentioned, it's been a very popular year for pharmacy
- 2:06Speaker 5: issues at the federal level, and I expect to see
- 2:09Speaker 5: some of that happen after the election. So in DC
- 2:12Speaker 5: Congresses in recess right now, they will not return until
- 2:16Speaker 5: November twelfth, and we call that period from after the
- 2:19Speaker 5: election to the end of the year lame duck, and
- 2:21Speaker 5: it's the last opportunity for congressional legislation to pass before
- 2:26Speaker 5: it has to be reintroduced at the beginning of a
- 2:28Speaker 5: new Congress, which will start in January.
- 2:32Speaker 1: I think that the outcome.
- 2:34Speaker 5: Of the presidential and congressional elections could have some implications
- 2:39Speaker 5: for what Congress gets done at the federal level during
- 2:42Speaker 5: that lame duck period. But I do anticipate there will
- 2:45Speaker 5: be a health care package and that pharmacy issues, PBM reform,
- 2:50Speaker 5: possibly maybe some small things around three p forty bter
- 2:57Speaker 5: telehealth related legislation could be up for play in that
- 3:00Speaker 5: lame duck period.
- 3:01Speaker 4: Now, even with the election results happening, we still have
- 3:05Speaker 4: bipartisan support from both sides on a lot of the
- 3:08Speaker 4: pharmacy legislation that's in the House right now. Brian, from
- 3:11Speaker 4: your standpoint, where do you see happening here at the
- 3:13Speaker 4: end of the year.
- 3:14Speaker 6: Yeah, So the state level is a lot quieter for once. Actually,
- 3:18Speaker 6: most state legislatures are out of session for the year.
- 3:21Speaker 6: There are a handful of state legislatures that are full
- 3:24Speaker 6: time and kind of in session calendar year round, Ohio, Pennsylvania,
- 3:29Speaker 6: Michigan being a handful. But they're really not doing anything
- 3:32Speaker 6: either there, right because they're all getting elected or trying
- 3:35Speaker 6: to get elected. And then similarly to the federal side,
- 3:38Speaker 6: they will at times do a lame duck session. Depends
- 3:41Speaker 6: on the state, depends on the issues, depends on what
- 3:44Speaker 6: happened in the election. So we'll see what happens there.
- 3:46Speaker 6: There could be a possibility of a lame duck here
- 3:48Speaker 6: in Ohio. What gets done there if it happens, who knows,
- 3:52Speaker 6: Probably not too much. On the pharmacy side, a couple
- 3:55Speaker 6: of small bills that we're keeping an eye on, but
- 3:57Speaker 6: nothing too substantial unlike what could happen at the federal.
- 4:00Speaker 4: Level from an efficacy standpoint. How does this affect you
- 4:03Speaker 4: guys towards the end of the year. I'm just curious.
- 4:05Speaker 1: Yeah, I love that question.
- 4:07Speaker 5: One of the things I think sometimes people may not
- 4:10Speaker 5: realize always about Cardinal Hill's government relations team is.
- 4:13Speaker 1: We lobby everybody.
- 4:15Speaker 5: We lobby at the federal level, both sides of the
- 4:18Speaker 5: aisle and both chambers of government. Now, we do know
- 4:21Speaker 5: that at this point, either way, there will be a
- 4:24Speaker 5: new administration, and we will work with whatever a new
- 4:26Speaker 5: administration is elected. But I think that the actual outcome
- 4:30Speaker 5: of an election by election does not completely overhaul what
- 4:36Speaker 5: our congressional, legislative and regulatory priorities are. As you mentioned
- 4:41Speaker 5: at the beginning, especially when it comes to pharmacy issues.
- 4:44Speaker 5: The majority of things that we're working on, we're monitoring
- 4:46Speaker 5: and tracking do have by partisan interest. So we will
- 4:48Speaker 5: still be talking to both Democrats and Republicans for any
- 4:52Speaker 5: wins on the pharmacy front, regardless of the election outcoming,
- 4:55Speaker 5: regardless of who's in the majority in the House and
- 4:57Speaker 5: in the Senate.
- 4:58Speaker 3: What about from you Brin, Yeah.
- 5:00Speaker 6: I think at this point of the calendar and where
- 5:02Speaker 6: the elections are and looking into twenty twenty five, we're
- 5:05Speaker 6: really at a planning portion.
- 5:06Speaker 3: You know.
- 5:07Speaker 6: We're at that space where we're planning on what states
- 5:10Speaker 6: are going to be very active in twenty twenty five,
- 5:12Speaker 6: what issues are going to be active in what states,
- 5:14Speaker 6: and where we may be able to see some advancements
- 5:17Speaker 6: for pharmacy, whether that's in scope of practice or in
- 5:19Speaker 6: PBM reform or whatever it may be.
- 5:21Speaker 3: So it's really one of these calm before the storms.
- 5:25Speaker 3: I'll call it.
- 5:26Speaker 6: A lot of states will start doing pre introductions of
- 5:29Speaker 6: bills here right after the election, once they know that
- 5:31Speaker 6: they're actually reelected, So we'll get a good sense of
- 5:34Speaker 6: what's coming, you know, early twenty twenty five, because state
- 5:38Speaker 6: sessions are really quick. Virginia has a thirty day session
- 5:41Speaker 6: next year, so things move very very quickly at the
- 5:43Speaker 6: state level, So.
- 5:44Speaker 3: You have to be prepared ahead of time.
- 5:46Speaker 6: And this planning time is really key for us just
- 5:48Speaker 6: to kind of get a sense of what's coming, where
- 5:50Speaker 6: it's coming, and how we want to engage, if we
- 5:52Speaker 6: want to engage.
- 5:52Speaker 4: It's going to say the planning must be absolutely crazy
- 5:55Speaker 4: at this time of the year, especially when you don't
- 5:57Speaker 4: know when you have tight races, and then you have
- 6:01Speaker 4: certain races that you might not worry about, but those
- 6:03Speaker 4: tight ones are probably a little bit too close to call.
- 6:05Speaker 3: Yeah, And I think at the state, at the state
- 6:06Speaker 3: level too.
- 6:07Speaker 6: You know, obviously, you know, Jerico gets to deal with
- 6:09Speaker 6: one government, right one legislature on Congress, I'm doing fifty
- 6:13Speaker 6: different ones, and you know they vary, right. A legislature
- 6:17Speaker 6: in Massachusetts is very different than Utah, right, So and
- 6:21Speaker 6: the issues don't really change all that much, but the
- 6:23Speaker 6: messaging does, so it's really it's really interesting to see
- 6:25Speaker 6: how that works at the federal level.
- 6:27Speaker 5: I'm kind of ready for any type of wildcard. This
- 6:29Speaker 5: is it's an unprecedented year in so many ways. There
- 6:33Speaker 5: are always these surprises. To your point, Jason, there's always
- 6:36Speaker 5: that race that you thought was safe that on election
- 6:39Speaker 5: day gets flipped and maybe flips party or or things
- 6:43Speaker 5: of you know, the incumbent loses. But there are also
- 6:46Speaker 5: so many retirements that have already been announced at the
- 6:49Speaker 5: federal level, so we know that from a demographic standpoint,
- 6:52Speaker 5: we're looking at a lot of change and a lot
- 6:54Speaker 5: of turnover.
- 6:55Speaker 1: So we are waiting to see.
- 6:56Speaker 5: Like what the outcome will be, specifically for cardinals health
- 7:00Speaker 5: where we have large footprints in those states and those districts.
- 7:03Speaker 1: Who will be the people that we are working with.
- 7:06Speaker 5: Will there be more people with pharmacy or healthcare related
- 7:09Speaker 5: backgrounds that end up being elected. Will they make those
- 7:12Speaker 5: their priorities? Where do we need to strategize about who
- 7:15Speaker 5: we meet? But I'm kind of ready for anything at everything.
- 7:18Speaker 5: At the federal level, it can seriously go either way.
- 7:21Speaker 5: I do I think short of a sweep, which we
- 7:23Speaker 5: have to acknowledge could always happen.
- 7:25Speaker 1: I do still think we're looking at a divide to
- 7:26Speaker 1: Congress next.
- 7:27Speaker 4: Year, though, Yeah, I would agree, just based on what
- 7:29Speaker 4: I've seen in the past. So well, let's step into
- 7:32Speaker 4: it here, looking to twenty twenty five at the state
- 7:35Speaker 4: and federal level. All right, let's get to the big one.
- 7:38Speaker 4: Back in July, lawmakers introduced a bipartisan bill, as I mentioned,
- 7:41Speaker 4: a crackdown on PBMs. There was an investigation, a House
- 7:45Speaker 4: committee hearing, all of ensure the community pharmacists are reimbursed fairly.
- 7:49Speaker 4: So where are we with PBM reform at the present time?
- 7:53Speaker 5: Excellent, excellent question. I'm glad you gave the background and
- 7:56Speaker 5: the context there. I cannot remember Congress before this where
- 8:00Speaker 5: there's been this much advancement on PBM reform. And then
- 8:05Speaker 5: to your point, you mentioned that we did get the
- 8:06Speaker 5: outcome of the Federal Trade Commission investigation. In the House
- 8:10Speaker 5: Oversight Committee the results of their investigation as well.
- 8:13Speaker 1: So where we send on the legislative front.
- 8:15Speaker 5: There is a package reay to go in the House
- 8:18Speaker 5: and a package way to go in the Senate. But
- 8:20Speaker 5: those packages do not exactly look the same. So the
- 8:23Speaker 5: pathway to passage during lame duck, is one chamber or
- 8:27Speaker 5: the other needs to take the initiative to get support
- 8:31Speaker 5: from the other side if there's going to be any
- 8:34Speaker 5: movement during lame duck. Now, both of those packages contain
- 8:38Speaker 5: a lot of the provisions that the pharmacy communities have
- 8:41Speaker 5: been educating Congress on for the past two years. Banning
- 8:44Speaker 5: spread pricing and Medicare and Medicaid transparency around rebates, more
- 8:50Speaker 5: transparency around reporting, banning patient steering, prohibiting PBMs from paying
- 8:56Speaker 5: affiliated pharmacies more than they pay independent pharmacies. A lot
- 9:00Speaker 5: of the big provisions that they've been educating on the
- 9:03Speaker 5: last couple of years are maintained in both of those packages,
- 9:06Speaker 5: and both have bipartisan support. So it really will just
- 9:10Speaker 5: take you know, what will be the foundation and base
- 9:12Speaker 5: of a healthcare legislative package during the lame duck and
- 9:15Speaker 5: getting both sides of the out degree on one PBM reform.
- 9:18Speaker 5: I will say that I think even if there is
- 9:21Speaker 5: some if there is some measures of PBM reform that
- 9:25Speaker 5: pass at the end of this year, I don't think
- 9:27Speaker 5: that's when we put the I don't think that's when
- 9:29Speaker 5: advocates put the.
- 9:30Speaker 1: Pencils down on PBM reform.
- 9:31Speaker 5: I think that that is still an issue that will
- 9:33Speaker 5: carry over going an ongoing issue. I don't think that maybe,
- 9:38Speaker 5: you know, again I kind of mentioned the big ones
- 9:40Speaker 5: there and overlaid them and again anticipation that some of
- 9:44Speaker 5: them can pass, maybe not all of them done. I
- 9:46Speaker 5: think that the work will continue into next year either way.
- 9:49Speaker 4: Before we get to a state levels perspective. I mentioned
- 9:52Speaker 4: two different types of PBM reform bills.
- 9:55Speaker 3: How does that happen?
- 9:56Speaker 1: How does each chamber has different priorities?
- 10:00Speaker 2: Yeah?
- 10:00Speaker 5: Interesting, Yeah, I would say that the Senate bill MEPA,
- 10:04Speaker 5: and I apologize it should have come prepared with what
- 10:06Speaker 5: there's so many acronyms for the PBM measures have taken
- 10:12Speaker 5: into account reforms that the Senate Help Committee has been
- 10:16Speaker 5: looking at for the past several years.
- 10:18Speaker 1: And then on the House side.
- 10:20Speaker 5: The package they passed it was actually there were more
- 10:23Speaker 5: provisions beyond just PBM. There were hospital transparencies, some payment
- 10:26Speaker 5: transparency provisions on the House side as well. So it's
- 10:30Speaker 5: totally it's not uncommon at all two different chambers to
- 10:33Speaker 5: kind of start with their own direction and then hope
- 10:37Speaker 5: that they come to the table for some type of
- 10:38Speaker 5: reconciliation to hopefully agree on the same outcome.
- 10:41Speaker 4: Interesting, all right, Brian. From a state level, what do
- 10:44Speaker 4: you see in PBM reform happening?
- 10:47Speaker 3: Yeah, it's not going away.
- 10:49Speaker 6: I think last year twenty four states passed PBM bills
- 10:53Speaker 6: across the country, and to Jeriko's point, pencils aren't down right,
- 10:56Speaker 6: that's continuing. You know, California passed bill lighton session. It
- 11:00Speaker 6: was actually vetoed by the governor. He plans to introduce
- 11:03Speaker 6: his own version of a PBM bill next year, So
- 11:05Speaker 6: I think that's all eyes are going to be there.
- 11:07Speaker 6: I think Texas is looking at a PBM bill, So
- 11:09Speaker 6: there's going to be a lot of action in the states.
- 11:11Speaker 6: You know, all of these PBM bills that we've seen
- 11:14Speaker 6: largely focused on increased transparency, improved reporting, prohibiting PBMs from
- 11:19Speaker 6: employing tactics like clawbactor, gad clauses. Some states are aren't
- 11:22Speaker 6: going to step further.
- 11:23Speaker 3: Right. West Virginia is a really good example. They've they've instituted.
- 11:26Speaker 6: A rap floor in the commercial market, which is kind
- 11:28Speaker 6: of unheard of in that space. So a lot of
- 11:30Speaker 6: states on looking at West Virginia and see you know,
- 11:33Speaker 6: all right, we've got this, we got this step one
- 11:35Speaker 6: of a PBM reform, and where where can we go
- 11:37Speaker 6: from here?
- 11:37Speaker 3: And and what doesn't look like?
- 11:38Speaker 6: So I think I think we're going to see a
- 11:40Speaker 6: lot of that kind of language introduced in the states
- 11:43Speaker 6: where I don't know yet, but but we'll certainly be
- 11:45Speaker 6: watching very closely. PBM reform at the state level is
- 11:49Speaker 6: by far the number one introduced topic in state legislatures.
- 11:54Speaker 6: It's it's in every state at some level, multiple versions
- 11:58Speaker 6: of it, all the bills kind of you kind of
- 12:00Speaker 6: to your point earlier.
- 12:01Speaker 3: So we'll keep a close eye on it.
- 12:03Speaker 6: But you know, I think California, Texas, and then obviously
- 12:05Speaker 6: there's always some some random state that pops up and
- 12:07Speaker 6: gets some pretty good moementre.
- 12:08Speaker 4: So it's interesting from a house in Congress standpoint, you know,
- 12:12Speaker 4: those two entities kind of live in their own bubble.
- 12:15Speaker 4: What happens on a state level when there's so much movement,
- 12:18Speaker 4: does that generally affect what happens at a federal level
- 12:21Speaker 4: or do they not see that happening or how.
- 12:24Speaker 3: Does that work?
- 12:25Speaker 5: My counterpart would love love the answer to this, because
- 12:29Speaker 5: this is it's a it's a friendly debate typically between
- 12:33Speaker 5: federal and state lobbyists about where the work actually gets done.
- 12:38Speaker 5: I will concede to my counterpart here that states typically
- 12:41Speaker 5: are the model. It typically takes a state or several
- 12:45Speaker 5: states passing up several bills related to one topic for
- 12:49Speaker 5: that to then become the foundation of what ultimately is
- 12:52Speaker 5: a legislative package at the federal level.
- 12:54Speaker 3: Yeah. I always joke with Jaka that wow, conceding that
- 12:57Speaker 3: nothing ever happens in DC. Yeah, yeah, yeah, I always don't.
- 13:03Speaker 3: Don't happen changing lives at the table. This is crazy.
- 13:05Speaker 6: But it all comes from the states because I mean,
- 13:07Speaker 6: even think about it from the PBM side of the lens, right,
- 13:10Speaker 6: if they are operating in off fifty states and thirty
- 13:12Speaker 6: states have different a patchwork of policies and requirements, and
- 13:16Speaker 6: that's not easy for them to to to abide by. Right,
- 13:20Speaker 6: So that's when you know it makes sense for the
- 13:22Speaker 6: federal government to actually do something and pass something. But
- 13:26Speaker 6: but Jerick is right, largely those will mimic or be
- 13:30Speaker 6: similar to to what the states do at least of
- 13:33Speaker 6: some degree.
- 13:34Speaker 3: No, that's interesting.
- 13:36Speaker 4: Uh, let's dive into another topic here, that's that's on
- 13:39Speaker 4: everybody's mind, and that's drug shortages. Currently we have a
- 13:43Speaker 4: little bit what over three hundred active drug shortages, which
- 13:46Speaker 4: is the most since two thousand and three. Since drug
- 13:48Speaker 4: shortages have been have started to get tracked in such
- 13:51Speaker 4: a way what sort of federal and state legislation can
- 13:54Speaker 4: be done to mitigate further drug shortages and can anything
- 13:58Speaker 4: be mitigated?
- 14:00Speaker 5: Uh, this is We've done a lot of of advocacy
- 14:03Speaker 5: in this area over the past year and a half
- 14:06Speaker 5: on the federal side, Jason, to your point to it's
- 14:09Speaker 5: starting to be tracked. This started to become more of
- 14:12Speaker 5: an issue early last year when there was a shortage
- 14:16Speaker 5: of controlled substances I believe it you know, related to
- 14:21Speaker 5: to adderall and then some shortages of some cancer products
- 14:25Speaker 5: as well, and it led to a larger discussion in
- 14:28Speaker 5: Congress about shortages.
- 14:30Speaker 1: Of generics and what is the start of.
- 14:33Speaker 5: Them, and who's responsible for them and what you know,
- 14:35Speaker 5: what do we need to do to get involved. So
- 14:38Speaker 5: we have done a lot of educating from the point
- 14:41Speaker 5: of a healthcare distributor about what our role is in
- 14:44Speaker 5: mitigating shortages and what role the distributor plays. When you've
- 14:48Speaker 5: seen one shortage, you've seen one shortage, so there is
- 14:52Speaker 5: not going to be one reason that shortages happened. There
- 14:54Speaker 5: are short term shortage shortages, there are long term, long
- 14:58Speaker 5: term shortages, and there will. In addition, there's not one
- 15:02Speaker 5: solution to stop drug shortages. So we have been in
- 15:06Speaker 5: to talk to Congress about what our role is, the
- 15:09Speaker 5: actions that we take, and then how we want to
- 15:12Speaker 5: work with them to incentivize hospitals, providers where it makes sense,
- 15:18Speaker 5: where it makes sense, to incentivize domestic manufacturing to try
- 15:23Speaker 5: to mitigate shortages where we can.
- 15:25Speaker 1: There have been a number.
- 15:26Speaker 5: Of legislative proposals that have been introduced at the federal
- 15:29Speaker 5: level as well. One bill that's been actually introduced, and
- 15:34Speaker 5: then there have been several proposals so they have not
- 15:36Speaker 5: been formally introduced. They've introduced draft legislation that Cardinal Health
- 15:42Speaker 5: has responded to in kind, and also work with our
- 15:44Speaker 5: trade groups, the Healthcare Distributors Alliance to respond to them
- 15:49Speaker 5: as well about how we want to work with manufacturers,
- 15:52Speaker 5: how we want to work with pharmacies, how we want
- 15:54Speaker 5: to work together as everybody has a role to a
- 15:58Speaker 5: resilient health care supply chain.
- 16:01Speaker 1: I jury is still out for me.
- 16:03Speaker 5: As far as legislative proposals go if any of those
- 16:07Speaker 5: make it across the finish line over the next couple
- 16:09Speaker 5: of weeks. But again, I think another topic that continues
- 16:12Speaker 5: to carry over, but one that we have again been
- 16:15Speaker 5: out there in front of and responding to and kind
- 16:18Speaker 5: a lot this past year.
- 16:19Speaker 4: Do these proposals can they actually from a manufacturing standpoint,
- 16:24Speaker 4: affect a drug shortage situation?
- 16:27Speaker 3: How does how does that are?
- 16:29Speaker 4: Do you feel like they're getting into a point where
- 16:31Speaker 4: they can actually affect from a manufacturer's level to you know,
- 16:37Speaker 4: you know, ultimately affect the drug shortage problem?
- 16:39Speaker 1: Yet not tomorrow, okay.
- 16:41Speaker 5: But eventually, And I think and I think that that's
- 16:43Speaker 5: where I think some that's there were some of the
- 16:45Speaker 5: consternation could could come in and frustration could come in
- 16:49Speaker 5: because of many policy solutions that could exist, most likely
- 16:54Speaker 5: with drug shorties, you're going to have to implement them
- 16:56Speaker 5: many at the same time and simultaneously. The majority of
- 17:00Speaker 5: active pharmaceutical ingredients that it takes to to form drill
- 17:04Speaker 5: compounds and molecules are are not manufactured here domestically.
- 17:08Speaker 1: They are they are overseas.
- 17:11Speaker 5: So what are you know, what are things that we
- 17:13Speaker 5: could be doing around active ingredients to drive some of that,
- 17:16Speaker 5: and then and then beyond driving the manufacturing incentivized, incentivizing
- 17:22Speaker 5: providers and hospitals for purchasing domestically made products as well.
- 17:26Speaker 5: This is something that the f d A and other
- 17:29Speaker 5: agencies are looking at. This is something that's been looked
- 17:32Speaker 5: at a little bit longer when it comes to medical
- 17:34Speaker 5: supplies and medical products. It's it's getting a little bit
- 17:36Speaker 5: more traction on the pharmacide as well.
- 17:38Speaker 3: Interesting, Brian, from the state level, what are you seeing?
- 17:42Speaker 6: Not as much? It's this is at this point, I
- 17:44Speaker 6: think more of a federal issue. We are starting to
- 17:46Speaker 6: see some states introduce legislation, but it doesn't really see
- 17:49Speaker 6: any movement to date to require hospitals to stockpile so
- 17:53Speaker 6: they can try to, you know, go after the shortage
- 17:56Speaker 6: level at the hospital level. But outside of that, we
- 17:58Speaker 6: haven't really seen the whole trickle down to the states.
- 18:01Speaker 6: But again by joke earlier, they don't do anything in DC.
- 18:04Speaker 6: That's not fair joke. I grasp that. But the states
- 18:06Speaker 6: will start to engage at some level. What that looks
- 18:09Speaker 6: like I think that could be we find out in
- 18:11Speaker 6: twenty twenty five. I think the hospital stockpiling bill, it's
- 18:14Speaker 6: going to probably be one that we see across the country.
- 18:17Speaker 6: But what else comes on the shortage topic in the States,
- 18:20Speaker 6: I don't know yet.
- 18:20Speaker 4: Can you expand on the hospital stockpiling though for a
- 18:23Speaker 4: quick second.
- 18:24Speaker 6: Yeah, So the bill would essentially require hospitals to have
- 18:27Speaker 6: I believe a thirty day stockpile of their most used drugs.
- 18:30Speaker 6: I think there's a number, maybe it's ten or fifteen
- 18:32Speaker 6: that they're most used drugs, so that in the event
- 18:34Speaker 6: that there is a shortage on that medication, the hospital
- 18:37Speaker 6: can survive for those thirty days until they can find
- 18:39Speaker 6: some other avenue to acquire those drugs. It can create
- 18:43Speaker 6: issues both for the hospital just in a space situation, right,
- 18:47Speaker 6: they don't have a lot of extra space, but any
- 18:49Speaker 6: kind of return situation and price increase or decrease then
- 18:52Speaker 6: can be an issue for both the hospital and for us.
- 18:56Speaker 6: A cardinal can make.
- 18:57Speaker 1: Sure you're rotating expire drugs as well.
- 18:59Speaker 5: So this is exactly another another solution that we're looking
- 19:04Speaker 5: at at the federal side too. So not saying you know,
- 19:06Speaker 5: it's it's a bad thing, but just if you're going
- 19:08Speaker 5: to do that, it just needs to be one in
- 19:10Speaker 5: a way where you're not you don't end up actually
- 19:12Speaker 5: making the problem that you're trying to solve even worse
- 19:14Speaker 5: by exascergating.
- 19:15Speaker 3: Yeah.
- 19:16Speaker 4: I think what a lot of people tend to kind
- 19:18Speaker 4: of misconstrued is is, you know, it's a frustrating issue.
- 19:22Speaker 4: You know, people and families, you know need their medications,
- 19:25Speaker 4: but there's a lot of nuances that need to be
- 19:28Speaker 4: that need to be not only just modernized, but like
- 19:30Speaker 4: you said, kind of bringing stuff back to you know,
- 19:32Speaker 4: domestic and you know, making sure all those those fail
- 19:36Speaker 4: safes are in place, so it's not just a you know,
- 19:39Speaker 4: a one stop fix.
- 19:40Speaker 3: There's a lot of nuance to it.
- 19:43Speaker 4: One other thing I do want to get into is
- 19:45Speaker 4: something that I had read for the first time, and
- 19:47Speaker 4: that was the IRA. The Inflation Reduction Act introduced major
- 19:52Speaker 4: policy changes to the healthcare industry, raise important questions about
- 19:56Speaker 4: launch prices, pipeline strategy, evidence requires.
- 20:01Speaker 3: I was taking a deep.
- 20:02Speaker 4: Dive into this, Jerica, please explain this to me and
- 20:05Speaker 4: how this is working and how it's affecting pharmacies.
- 20:08Speaker 1: This is now turned into the IRA one oh one podcast. Jason.
- 20:14Speaker 5: Yes, the Inflation Reduction Act was landmark for a variety
- 20:18Speaker 5: of reasons that you have mentioned. So we are two
- 20:20Speaker 5: years into the enactment of this law. The other major,
- 20:26Speaker 5: the lynchpin of this law is that now the federal
- 20:30Speaker 5: government can negotiate the cost of drugs on behalf of Medicare,
- 20:35Speaker 5: and that is the large provision that CMS is in
- 20:39Speaker 5: the middle of implementing now. So Congress allocated a certain
- 20:42Speaker 5: amount of money for CMS to stand up an Office
- 20:45Speaker 5: of Drug Price Negotiation to implement all of the provisions
- 20:48Speaker 5: that you have mentioned over the course of ten years
- 20:53Speaker 5: in hopes that over the next few years they are
- 20:55Speaker 5: reducing the cost for Medicare beneficiaries the most cost drugs.
- 21:01Speaker 1: That are in that system.
- 21:02Speaker 5: So, a couple of weeks ago, CMS finalized Medicare Drug
- 21:07Speaker 5: Price Negotiation Guidance.
- 21:10Speaker 1: So I'll take a step back.
- 21:12Speaker 5: Actually, earlier this year in August, we knew, we found
- 21:15Speaker 5: out what the first ten negotiated products under Medicare Part
- 21:18Speaker 5: D will be. Patients will now have access to those
- 21:22Speaker 5: negotiated prices also known as maximum fair prices, beginning of
- 21:25Speaker 5: January twenty twenty six. The guidance that came out a
- 21:29Speaker 5: couple of weeks ago in October kind of walks through
- 21:31Speaker 5: steps for manufacturers and dispensing entities pharmacies, how they are
- 21:36Speaker 5: going to actually introduce those new prices into their system
- 21:40Speaker 5: to be active by January twenty twenty six.
- 21:43Speaker 1: If this is sounding as complicated as clear as.
- 21:45Speaker 5: Metsofarating to kind of hit the level of pharmacies, what
- 21:52Speaker 5: CMS decided to do was they decided that they are
- 21:55Speaker 5: going to have an outside vendor also known as a
- 21:57Speaker 5: Medicare Transaction Facilitator, the vendor that initiates the claims data
- 22:02Speaker 5: for these for these new prices. So both dispensers and
- 22:05Speaker 5: manufacturers have to interact with this vendor for claims data,
- 22:09Speaker 5: but manufacturers do not have to interact with this MTF
- 22:13Speaker 5: to pay pharmacies. So each manufacturer could take a different step.
- 22:18Speaker 5: The concern for pharmacies, I think with the with the
- 22:22Speaker 5: finalization of this guidance, as many.
- 22:24Speaker 1: First being cash flow concerns.
- 22:27Speaker 5: The guidance says that manufacturers have to pay pharmacies within
- 22:31Speaker 5: a fourteen day prompt window, but there is some discrepancy
- 22:35Speaker 5: I think within the guidance on win exactly that fourteen
- 22:37Speaker 5: day window begins. The guidance does set up a mechanism
- 22:41Speaker 5: for pharmacies that if they if you're a pharmacy that's
- 22:44Speaker 5: in a rural area, if you're a pharmacy where you
- 22:47Speaker 5: are dispensing many of these to negotiated products, that you
- 22:51Speaker 5: can set up with CMS to say, you know, proactively,
- 22:53Speaker 5: I think there could be some cash flow concerns and
- 22:56Speaker 5: how can I work better with with manufacturers and then
- 22:58Speaker 5: and the government on that. And then in these past
- 23:03Speaker 5: couple of days since this final guidance has been introduced,
- 23:05Speaker 5: there have also been a number of articles of from
- 23:08Speaker 5: independent pharmacies that are that are you know, anxious about
- 23:14Speaker 5: how reimbursement is going to work, and so they may
- 23:16Speaker 5: not stock these negotiated products. So then you run into
- 23:19Speaker 5: the concern of you know, it's supposed to be affordable
- 23:22Speaker 5: and available to patients, but if they still don't have
- 23:24Speaker 5: access to it for a variety of reasons, one that
- 23:25Speaker 5: pharmacy does not stock it, or that pharmacy becomes underwater
- 23:28Speaker 5: because they're not reimbursed in a timely manner, then it does,
- 23:32Speaker 5: you know, go back to what is the intent of
- 23:34Speaker 5: this after all?
- 23:34Speaker 1: So then then you get into a number.
- 23:38Speaker 5: Of the it's okay, I'm following, and then the and
- 23:43Speaker 5: then the market access piece.
- 23:45Speaker 1: That you that you've mentioned is introduced as well.
- 23:48Speaker 5: There were a number of concerns that's that that when
- 23:51Speaker 5: this this law was implemented, that it could delay or
- 23:56Speaker 5: prevent innovation of new products coming to mark because of
- 24:00Speaker 5: all the changes that are interesting factors have to make
- 24:03Speaker 5: as well. So there is another provision in the new
- 24:07Speaker 5: guidance that I believe allows manufacturers of biosimilar products to
- 24:12Speaker 5: delay to apply to CMS, to delay when their product
- 24:17Speaker 5: would be eligible for negotiation, to give it a little
- 24:20Speaker 5: bit more time to get into to the market. So
- 24:23Speaker 5: there's a couple of things there at play as well.
- 24:26Speaker 5: I think on the related to the guidance. On the
- 24:29Speaker 5: congressional side, there are a couple of pieces of bills
- 24:31Speaker 5: that are looking at biosimilar is being interchangeable as soon
- 24:35Speaker 5: as they are introduced into market and getting rid of
- 24:37Speaker 5: switching studies to try to also have an uptake there
- 24:40Speaker 5: as well. So if you think few different things, they're
- 24:42Speaker 5: playing with market access as well.
- 24:44Speaker 4: Anythink from a state level, Brian in this space or
- 24:46Speaker 4: is it still too early?
- 24:47Speaker 6: Yeah, I think it's too early. Credit work credits. Do
- 24:50Speaker 6: DC actually did something here?
- 24:51Speaker 5: Right?
- 24:51Speaker 3: I think of that joke.
- 24:52Speaker 6: But now at the state level, it's really just keeping
- 24:55Speaker 6: a close eye on what's happening with the inflementation and
- 24:57Speaker 6: roll out of the IRA. States are certainly keeping an island.
- 25:00Speaker 6: You know, how pharmacies are getting paid, and if they're
- 25:02Speaker 6: getting paid, what you know that that patent are able
- 25:06Speaker 6: to get their medications with no problems, and then on
- 25:09Speaker 6: the cost of the drugs and then how that.
- 25:11Speaker 3: Would correlate with the state medicaid.
- 25:13Speaker 6: Right, So I think that's where the future is going
- 25:15Speaker 6: to be for at the state level of Right, let's
- 25:17Speaker 6: see how this rolls out, and then can we do
- 25:19Speaker 6: something similar or help out our state medicaid at this
- 25:22Speaker 6: you know, to have these kind of the same prices.
- 25:24Speaker 4: The implementation part piece to this just seems like you said,
- 25:29Speaker 4: it's pretty muddy. But ultimately, if we have medicare medicaid
- 25:33Speaker 4: patients saving on this the vast amount of drugs because
- 25:36Speaker 4: it seems like it's gonna it sounds like it's going
- 25:38Speaker 4: to cover a lot of different aspects of patient's needs.
- 25:42Speaker 3: Is that is that accurate?
- 25:43Speaker 1: So they're rolling out a number of drugs.
- 25:46Speaker 5: So there's the formula, So we're ten negotiated products now
- 25:50Speaker 5: in February of next year, there will be an additional
- 25:53Speaker 5: fifteen negotiated products added. There's been a lot of talk
- 25:56Speaker 5: that it seems all but confirmed that GLP ones may
- 25:59Speaker 5: be this next list. Those drugs still under Medicare Part
- 26:03Speaker 5: D go into effect in twenty twenty seven. Then things
- 26:06Speaker 5: really get found in twenty twenty six because the number
- 26:09Speaker 5: of negotiated products goes up, but then it starts getting
- 26:11Speaker 5: into Medicare Part D and Part B. Okay, this final
- 26:16Speaker 5: guidance did add a little bit of clarification from cms's
- 26:19Speaker 5: standpoint about how what formula you know, they take into
- 26:23Speaker 5: consideration when they put a negotiated product on their list.
- 26:26Speaker 5: But manufacturers, if you're going to be on that list,
- 26:28Speaker 5: you find out when the public finds out.
- 26:30Speaker 1: Nobody gets the heads up there.
- 26:34Speaker 5: The other thing that I will add is that you know,
- 26:37Speaker 5: from cms's standpoint, I think they want this to this
- 26:42Speaker 5: roll out to be as streamlined I think from their
- 26:44Speaker 5: perspective as it possibly can be. They are going to
- 26:47Speaker 5: start over the next couple of weeks here monthly technical
- 26:50Speaker 5: calls with pharmacies to participate to walk them through the
- 26:55Speaker 5: implementation of this guidance. And so if there are pharmacies
- 26:59Speaker 5: that not receive an invitation from CMS. On their IRA page,
- 27:04Speaker 5: there should be a link for them to our SVP.
- 27:07Speaker 5: They should RSVP with their business name and their business
- 27:10Speaker 5: emails so CMS recognizes them as a pharmacy to get
- 27:13Speaker 5: access to these monthly calls and participate and ask questions there.
- 27:17Speaker 4: All right, so we're looking at first kind of I
- 27:20Speaker 4: don't want to say stockpiling is the right word, but
- 27:24Speaker 4: negotiating these specific products, getting them to a price that's
- 27:28Speaker 4: that's agreed upon. And then obviously you look at implementation,
- 27:32Speaker 4: next pipeline strategy, and then finally by twenty twenty six,
- 27:36Speaker 4: this all somehow comes together.
- 27:39Speaker 1: It has to, but it has a statue. Yeah, it's
- 27:42Speaker 1: so now that.
- 27:43Speaker 5: That final guidances is out that that clock does begin.
- 27:47Speaker 5: I believe at some point next year, entities will I believe,
- 27:52Speaker 5: have to relay more of their plans to CMS. Again,
- 27:56Speaker 5: you know, claims data will have to go through this
- 27:58Speaker 5: Medicare Transaction facilitator, but how dispensing entities will be will
- 28:02Speaker 5: be paid. I believe further plans need to be sent
- 28:04Speaker 5: to CMS, and I think a lot of questions that
- 28:08Speaker 5: you see online or we get is the Is there
- 28:10Speaker 5: anything that could stop it? Will anything about the election
- 28:14Speaker 5: outcome stop? You know, there are legal challenges to the
- 28:18Speaker 5: Inflation Reduction Act, all of them so far, for the
- 28:22Speaker 5: most part, have gone in the favor of the administration.
- 28:25Speaker 1: And I think that it's you know, Congress.
- 28:28Speaker 5: Is really absolutely hesitant to open up this law again,
- 28:32Speaker 5: and I don't think that there's time to do that
- 28:34Speaker 5: in the short window that we have for the remainder
- 28:37Speaker 5: of this Congress. So all things considered, I think that
- 28:40Speaker 5: that timeline that CMS has put forth to implement this law,
- 28:45Speaker 5: by each deadline.
- 28:46Speaker 1: Continues to go forth.
- 28:47Speaker 5: If anything does change in twenty twenty five, in my opinion,
- 28:51Speaker 5: and others listening in could want to dial in and
- 28:54Speaker 5: prove me wrong, I think it would take an Act
- 28:55Speaker 5: of Congress.
- 28:56Speaker 3: Okay, well, thanks for that overview.
- 28:58Speaker 4: Again, it's something I found wildly interesting and just wanted
- 29:01Speaker 4: to learn more. So I'm sure everybody listening just learned
- 29:05Speaker 4: alamaad the IRA.
- 29:06Speaker 3: So let's shift here.
- 29:08Speaker 4: Let's shift to the three forty B legislation, a program
- 29:11Speaker 4: that goes back to nineteen ninety two, and basically it's
- 29:15Speaker 4: to help hospitals care for low income patience communities. There's
- 29:18Speaker 4: been a large discrepancy though in what hospitals charged versus
- 29:22Speaker 4: what they are paid. Any updates on legislation here and Brian,
- 29:26Speaker 4: I'll kick it to you.
- 29:27Speaker 3: Yeah. Sure.
- 29:27Speaker 6: At the state level, three forty B legislation was very
- 29:30Speaker 6: popular in twenty twenty four, and I expected to be
- 29:32Speaker 6: again in twenty twenty five. Last year, we had a
- 29:35Speaker 6: bunch of states that proposed that manufacturers it would prohibit
- 29:38Speaker 6: manufacturers from interfering with the delivery of free forty B
- 29:41Speaker 6: drugs to contract identity. Apparently there were some manufacturers imposing
- 29:46Speaker 6: additional restrictions on what pharmacies could dispense through three forty B.
- 29:49Speaker 6: So that's that's kind of where the bill came from.
- 29:51Speaker 6: At times, wholesalers were included in that, so would we
- 29:54Speaker 6: would engage on that portion just the wholesaler language. This
- 29:58Speaker 6: was very much opposed by the manufacturers, so it was
- 30:01Speaker 6: a tough battle in those states, but a bunch of
- 30:05Speaker 6: those those bills did pass, you know, West Virginia and Maryland, Mississippi, Minnesota,
- 30:09Speaker 6: Missouri are a handful. I expect more to come next year. However,
- 30:13Speaker 6: we are also learning that the manufacturers are having their
- 30:16Speaker 6: own three forty B bills come out, So you know,
- 30:19Speaker 6: I know that at least one manufacturers concerned that that
- 30:22Speaker 6: hospitals are making too much money on three forty B medications,
- 30:25Speaker 6: So I know that was that was.
- 30:26Speaker 4: The biggest That was the biggest red flag that I
- 30:29Speaker 4: had that I had seen exactly.
- 30:31Speaker 3: Yeah.
- 30:31Speaker 6: So yeah, so you kind of have these conflicting policy
- 30:34Speaker 6: ideas and we'll see where that goes. In twenty twenty five,
- 30:37Speaker 6: I know at least one state will have the the
- 30:40Speaker 6: new version from the manufacturers introduced. I think they'll also
- 30:44Speaker 6: have the other side too, So it'll be interesting to
- 30:46Speaker 6: see how that dynamic works out and if there's some
- 30:48Speaker 6: sort of compromise that they can make, because what's happening,
- 30:51Speaker 6: what the pharmacies and the f hds are seeing is
- 30:54Speaker 6: a lot of manufacturers as pulling out the three forty
- 30:57Speaker 6: B total totally right, So when they're not, when they're
- 31:00Speaker 6: not in there, not supplying their medication through it, then
- 31:04Speaker 6: there's an obviously issue, right, So hopefully there can be
- 31:07Speaker 6: some sort of compromise at the state level, and obviously
- 31:09Speaker 6: it's a federal program and at the same level, we
- 31:11Speaker 6: really don't get involved too much you know, we keep
- 31:13Speaker 6: an eye on it to you know, wholesalers we're included,
- 31:15Speaker 6: and then you know, we'll engage. But outside of that,
- 31:17Speaker 6: we're really just a the minoring process there. But it's
- 31:21Speaker 6: it's certainly a very popular subject at the state level.
- 31:24Speaker 4: All right, all right, Jerick, I got to ask, now,
- 31:25Speaker 4: because there's so much as happening on the state level,
- 31:28Speaker 4: what's going on federally?
- 31:29Speaker 5: Yeah, for once, for once, I can come back and say,
- 31:33Speaker 5: for three forty B this is not typically in one
- 31:37Speaker 5: Congress do we see a ton of federal legislation related
- 31:40Speaker 5: to the three forty B program. But that has been different.
- 31:43Speaker 5: In twenty twenty four, both the House and the Senate
- 31:47Speaker 5: have introduced three forty B bills. To Brian's point about
- 31:50Speaker 5: conflicting policies and by partisan engagement, I think we're seeing
- 31:54Speaker 5: some of that at.
- 31:54Speaker 1: The federal level as as well.
- 31:58Speaker 5: On the Senate side, there are what they call the
- 32:00Speaker 5: Gang of Six. There's six my partisan senators that we
- 32:04Speaker 5: are awaiting a large three forty B package that we
- 32:07Speaker 5: thought we would see before Congress recessed before heading into
- 32:10Speaker 5: the election.
- 32:10Speaker 1: Here something that could still pop up during lame duck.
- 32:13Speaker 5: But I think the next Congress one hundred and nineteen
- 32:17Speaker 5: Congress is the year of the year of three forty
- 32:19Speaker 5: b I think that's when you see some actual federal
- 32:21Speaker 5: I will say, they introduce bills. I don't think much
- 32:23Speaker 5: is going to be done with them, but I think
- 32:26Speaker 5: that that is that that will be a topic that's
- 32:29Speaker 5: more heavily discussed on the federal side next year than
- 32:31Speaker 5: it typically has been.
- 32:32Speaker 6: Yeah, I think just to piggyback off of that, I think,
- 32:35Speaker 6: you know, if there are new ideas introduced at the
- 32:37Speaker 6: federal level, you may see some states trying to run
- 32:39Speaker 6: with those and see how they see how it plays
- 32:41Speaker 6: out and name that state.
- 32:43Speaker 3: Right, So it's certainly going to.
- 32:45Speaker 6: Be an interesting world in three twenty five.
- 32:48Speaker 2: Wow.
- 32:48Speaker 3: Interesting.
- 32:49Speaker 4: Let's shift to provider status, which I know is on
- 32:54Speaker 4: a lot of people's minds. We've seen some evolution of
- 32:57Speaker 4: this in the last several years, so from my understanding,
- 33:00Speaker 4: out forty five bills in twenty seven states have been
- 33:03Speaker 4: signed into law roughly to expand the scope of practice
- 33:06Speaker 4: requirements and of course for pharmacists how to secure their
- 33:11Speaker 4: payment for these services. However, they currently lack the ability
- 33:14Speaker 4: to reliably bill for these services.
- 33:17Speaker 3: So what's the latest.
- 33:19Speaker 4: Especially we've seen I think a lot more movement here
- 33:21Speaker 4: from a state perspective.
- 33:22Speaker 6: So, Brian, what do you have for us? Yeah, your
- 33:24Speaker 6: numbers are really good. Forty eight bills in twenty seven states.
- 33:29Speaker 6: Spot on there. Yeah, this isn't an area where we're
- 33:33Speaker 6: seeing a lot of movement over the past couple of years.
- 33:36Speaker 3: I think it's going.
- 33:36Speaker 6: To start slowing down at the state level in twenty
- 33:38Speaker 6: twenty five, just because a lot of states worked on
- 33:40Speaker 6: this and have done something right to those numbers.
- 33:43Speaker 3: Credit.
- 33:44Speaker 6: A lot of this goes back to COVID, and during COVID,
- 33:47Speaker 6: the federal government institute of the PREP Act, which allowed
- 33:51Speaker 6: pharmacies to vaccinate down to age three and do test
- 33:55Speaker 6: and treat for COVID and flu.
- 33:59Speaker 3: People have gotten used to a right.
- 34:01Speaker 6: You know, you have a I have a three year
- 34:02Speaker 6: old daughter, I can take her to my local CVS,
- 34:04Speaker 6: my local and dependent pharmacy and get her vaccinated. That
- 34:07Speaker 6: that was that could go away right the federal government.
- 34:09Speaker 6: The PREP Bactic expires at the end of the year,
- 34:11Speaker 6: allegedly unless it's extended. But then then every state has
- 34:16Speaker 6: our own state laws on what you're able to do.
- 34:18Speaker 6: What a pharmacist is able to do. So that was
- 34:20Speaker 6: really a big focus was on immunizations, right, allowing pharmacists
- 34:23Speaker 6: and technicians to vaccinate down to age three or or
- 34:26Speaker 6: whatever compromised age that that you know, we came up with.
- 34:30Speaker 6: The test and treat portion of the scope of practice
- 34:33Speaker 6: and provider status is something that I think is ongoing.
- 34:36Speaker 6: You bring up a really good point though, on billing, right,
- 34:40Speaker 6: we worked this bill in Delaware a couple of years ago.
- 34:43Speaker 6: They have a test and treat bill there covid flu
- 34:46Speaker 6: strep throad. I believe it is, and it requires in
- 34:50Speaker 6: that language it requires payment from insurance. So that's I
- 34:52Speaker 6: believe that's the only bill that only state that does
- 34:55Speaker 6: that right now, and it should be the model moving
- 34:57Speaker 6: forward and it will be. However, that the test and
- 35:00Speaker 6: treat language is always very contentious in the states. The
- 35:03Speaker 6: physician groups oppose all the time. They don't want that
- 35:09Speaker 6: scope creep. And then when you bring in that that
- 35:12Speaker 6: payment requirement, then you get the health plans included and
- 35:15Speaker 6: they come in. So it makes it a little bit harder,
- 35:17Speaker 6: but not impossible obviously, as it did already pass in
- 35:19Speaker 6: one state. So we'll certainly be out there on this.
- 35:23Speaker 6: This is something this year in Ohio we authored a
- 35:26Speaker 6: letter to support on immunization. I know Ohio is trying
- 35:29Speaker 6: to do some test and treat next year too, so
- 35:31Speaker 6: we'll be we'll certainly be out there to support that
- 35:33Speaker 6: as well.
- 35:34Speaker 3: We replicated that.
- 35:35Speaker 6: Letter in Pennsylvania and are doing so in New Jersey too,
- 35:37Speaker 6: So we're happy to engage on this and something that
- 35:40Speaker 6: that I'm pretty close to, so I'm really happy to
- 35:43Speaker 6: work on it. It's it's very very popular, but again
- 35:47Speaker 6: there's always that that push back the immunization. I think
- 35:50Speaker 6: immunization side again, it's almost done. I think there's one
- 35:53Speaker 6: or two states. Texas is a weird state. They only
- 35:54Speaker 6: meet every other year, so they have not been in
- 35:56Speaker 6: session last year, so this year will be a big
- 35:59Speaker 6: one for them for both you know, a musations.
- 36:02Speaker 4: I mean, obviously COVID kind of vaulted pharmacists. Independent pharmais
- 36:05Speaker 4: into the spotlight, and they were seeing in such a
- 36:07Speaker 4: vital piece of the community healthcare, and you know how
- 36:12Speaker 4: those pieces come together. When you can't go to your physition,
- 36:14Speaker 4: let's go to your pharmacist. So I don't know, it
- 36:16Speaker 4: just seems kind of a no brainer. To me, But Jerica,
- 36:19Speaker 4: I don't know. I don't like your face right now.
- 36:20Speaker 4: You're giving me your You're like, I don't know.
- 36:25Speaker 1: We think it's a no brainer too, And I think
- 36:28Speaker 1: the scrunch face is because we are so close to
- 36:31Speaker 1: the finish line at the federal level.
- 36:33Speaker 5: And you know, I've been on previous podcasts and it's
- 36:36Speaker 5: still the same bill at the federal level. It's the
- 36:39Speaker 5: Equitable Community Access to Pharmacist Services Act.
- 36:43Speaker 1: The bill has.
- 36:43Speaker 5: Advanced this Congress so much further than it has last
- 36:46Speaker 5: you know, we do. We now have a bill in
- 36:48Speaker 5: the House, We have a bill in the Senate. We
- 36:50Speaker 5: have been working hard to advance co sponsors and support.
- 36:54Speaker 5: We have over one hundred co sponsors of this bill
- 36:56Speaker 5: on the House side, now bipartisan in both chambers. The
- 37:00Speaker 5: bill has been scored by the Congressional Budget Office. Now
- 37:03Speaker 5: we just need to land this plane. Cardinal Health is
- 37:08Speaker 5: still an active member of the Future of Pharmacy Care
- 37:12Speaker 5: Coalition that we're working in kind with with partners and
- 37:15Speaker 5: stakeholders and pharmacy groups, all using our collective voice to
- 37:19Speaker 5: hopefully advance this bill during Lane duck.
- 37:21Speaker 1: So that is the goal.
- 37:23Speaker 5: In addition to that one of the regulations that CMS
- 37:26Speaker 5: came out with earlier this year actually recommended independent and
- 37:31Speaker 5: retail pharmacists continued to get reimbursed. ORIED codified a provision
- 37:36Speaker 5: to get reimbursed under Part B for Hepatitis B vaccines.
- 37:40Speaker 5: Cardinal Health submitted a letter to CMS in support of
- 37:44Speaker 5: this provision and also alluded to their other federal provider's
- 37:48Speaker 5: status efforts similar to this legislation that we're also supporting
- 37:52Speaker 5: for that that pharmacists should get reimbursed for these services.
- 37:56Speaker 5: So we are we are actively going forward and hoping
- 37:59Speaker 5: that we can pull a in during the slam dug
- 38:02Speaker 5: period at the federal level as well. Still have had
- 38:05Speaker 5: that same opposition at the federal level as well from
- 38:08Speaker 5: physician groups, but remain open to communication and working together
- 38:13Speaker 5: to hopefully we can get that went across.
- 38:15Speaker 3: I like the analogy the plane is circling let's land.
- 38:17Speaker 1: It's land, it.
- 38:20Speaker 3: All right.
- 38:20Speaker 4: So lastly, I do want to sort of a trendy
- 38:24Speaker 4: topic that we've seen in the last several years, and
- 38:28Speaker 4: the popular subject called food is medicine, which is the
- 38:31Speaker 4: philosophy that uses food and nutrition to prevent, manage, and
- 38:35Speaker 4: treat disease. We have seen many pharmacies start to embrace
- 38:39Speaker 4: this philosophy. We were even going to be talking about
- 38:42Speaker 4: it at RBC for a little bit from a stage perspective.
- 38:45Speaker 4: So what kind of investment are we looking at for
- 38:47Speaker 4: the future of this ideology.
- 38:49Speaker 5: So a lot of it is, to your point, happening
- 38:52Speaker 5: outside of the government right now. A lot of pharmacies
- 38:57Speaker 5: are partnering with other companies like instact hard even to
- 39:00Speaker 5: make this happen. A lot of grocery store pharmacies, so
- 39:02Speaker 5: obviously where you're going to get your groceries and you
- 39:04Speaker 5: can get your prescription field as well. This was a
- 39:07Speaker 5: topic that was bought to us by a lot of
- 39:09Speaker 5: the customers that we work with, and you know, are
- 39:11Speaker 5: there initiatives that we can collaborate and support at the
- 39:16Speaker 5: federal level to get retail pharmacists, retail and independent pharmacists
- 39:21Speaker 5: more involved. So earlier this year, Cardinal Health submitted what
- 39:25Speaker 5: we call appropriations report language, so every appropriations bill has
- 39:28Speaker 5: an accompanying report.
- 39:30Speaker 1: We submitted and were able to.
- 39:32Speaker 5: Secure report language for Congress to start a pilot program
- 39:38Speaker 5: and involve independent and retail pharmacists and any food is
- 39:41Speaker 5: medicine initiatives that they are going to come out with. Additionally,
- 39:45Speaker 5: other report language that we secured actually increased funding to
- 39:49Speaker 5: a pilot program that was enacted last Congress and increased
- 39:52Speaker 5: it by a million dollars for next Congress, and that
- 39:55Speaker 5: hopefully that that pharmacists can.
- 39:57Speaker 1: Play a more vital role.
- 39:58Speaker 5: So as we continue to see if there's going to
- 40:01Speaker 5: be legislation, if there's any regulations or any areas where
- 40:04Speaker 5: it makes sense for us as Cardinal Health and working
- 40:07Speaker 5: within on behalf of our customers to collaborate, we want
- 40:09Speaker 5: to continue to support it.
- 40:11Speaker 4: I see it as kind of a natural fit for
- 40:14Speaker 4: you know, even going back to provider status, because you
- 40:16Speaker 4: already have pharmacies that are you know, servicing patients as
- 40:19Speaker 4: far as nutrition, as far as weight loss which helps
- 40:22Speaker 4: with lowering cholesterol, heart disease, and everything else that encompasses that.
- 40:27Speaker 4: So it's kind of a nice little, you know, pathway
- 40:30Speaker 4: into that same legislation. What about you, Brian, you've seen
- 40:32Speaker 4: anything you know being this this ideology being embraced from
- 40:37Speaker 4: a state level.
- 40:38Speaker 3: Not yet. I think it's coming.
- 40:39Speaker 6: I think it's going to be us leading it or
- 40:41Speaker 6: others leading it and just educating state medicaid offices, state legislators,
- 40:46Speaker 6: whoever it may be about it. I just think it's
- 40:48Speaker 6: not out there in the in the in their realm
- 40:51Speaker 6: and their space yet. But it's something that we're certainly
- 40:53Speaker 6: going to work on, you know, twenty twenty five, twenty
- 40:55Speaker 6: twenty six in the future. I think you know what
- 40:57Speaker 6: the federal government does. You know, they're the leader on
- 40:59Speaker 6: this right now. You know, if they have a report
- 41:01Speaker 6: or legislation, that's where then we can take and say, like, okay, look,
- 41:05Speaker 6: the federal looking at this running joke, they're not ever
- 41:08Speaker 6: going to do anything, so let's do it at the
- 41:10Speaker 6: state level. So so you know, we could see that
- 41:13Speaker 6: happening over the next couple of years. I know that
- 41:15Speaker 6: there are some states state medicaids in particularly that are
- 41:17Speaker 6: kind of in this realm. You know, Tennessee does something
- 41:20Speaker 6: with diapers, right, so kind of not food is medicine,
- 41:22Speaker 6: but kind of using you know, the medicaid benefit as
- 41:25Speaker 6: as you know, for something other than just the normal
- 41:28Speaker 6: medication that you would think of. So that could be
- 41:30Speaker 6: an opportunity to expand and make it a little bit
- 41:31Speaker 6: better because you know, reimbursements not great through that, but
- 41:34Speaker 6: something as a first step. It could be an avenue
- 41:36Speaker 6: for us.
- 41:37Speaker 4: All Right, guys, Well, before we wrap this up, we
- 41:39Speaker 4: talked about a lot of different subjects here, So I
- 41:41Speaker 4: just want to kind of give you guys a chance
- 41:44Speaker 4: to you know, kind of wrap us up in a
- 41:46Speaker 4: way where what what do we have as far as
- 41:48Speaker 4: the most the most current things to look for. We
- 41:52Speaker 4: we went through a lot of different subjects, so as
- 41:54Speaker 4: far as what's going to be happening sooner than later. Uh,
- 41:57Speaker 4: just kind of recap some of those now, and we'll
- 41:59Speaker 4: start with the state level.
- 42:00Speaker 6: Yeah, well, I mean I think elections are going to
- 42:01Speaker 6: be the first thing to keep see what happens for sure,
- 42:04Speaker 6: obviously the federal level, but at the state level too.
- 42:06Speaker 6: Essentially forty eight I think of the fifty state legislatives
- 42:09Speaker 6: are up for reelection. You know, there are a bunch
- 42:11Speaker 6: of governors ships up for election as well too, So
- 42:14Speaker 6: seeing what happens there, states will start moving real quick
- 42:17Speaker 6: when twenty twenty five comes comes around. You know. PBM
- 42:20Speaker 6: reform I think is going to be the one you
- 42:22Speaker 6: see the most right off the bat. And what happens
- 42:25Speaker 6: in those states that meet early and have short sessions
- 42:27Speaker 6: because things need to move quickly through those. That'll be
- 42:30Speaker 6: a really good indicator of what we see moving forward
- 42:32Speaker 6: on scope of practice side, I think, you know Test
- 42:34Speaker 6: and Tree, it is something that you know we can
- 42:36Speaker 6: see some movement early on and could develop some momentum.
- 42:39Speaker 6: So I think those two are kind of where I'm
- 42:41Speaker 6: focused right now.
- 42:42Speaker 3: Three p.
- 42:42Speaker 6: Forty B is the kind of the outlier because we
- 42:44Speaker 6: know it's coming, but we don't know what's coming right
- 42:45Speaker 6: so seeing what that is as well too, I think
- 42:48Speaker 6: are kind of where my focus is about.
- 42:49Speaker 5: You, Jerico, I'd have to say it actually looks a
- 42:51Speaker 5: lot very similar on the federal side as we started
- 42:55Speaker 5: with looking to see what the outcome of the elections
- 42:58Speaker 5: there as well. I will say in some whether you
- 43:00Speaker 5: are a federal or estate lobbyist or advocate, you will
- 43:04Speaker 5: be busy next year.
- 43:05Speaker 1: You'll be busy at the end of this year.
- 43:07Speaker 5: I think there will be no shortage of healthcare issues
- 43:11Speaker 5: that will continue to be a priority after the election
- 43:14Speaker 5: and coming into next year, and a lot of them
- 43:15Speaker 5: will involve pharmacies.
- 43:17Speaker 4: All right, guys, Well, I want to say thanks to
- 43:19Speaker 4: Jerk and Brian for joining us on the show to
- 43:20Speaker 4: provide a wealth of updates for all of our listeners.
- 43:22Speaker 4: I think it's going to be one we might want
- 43:24Speaker 4: to download twice and listen to a few times. Honestly,
- 43:27Speaker 4: it's all of you listening. Thanks for subscribing to the
- 43:29Speaker 4: Cardinal Health counter Talk podcast. If you haven't yet, make
- 43:31Speaker 4: sure you subscribe and download the Cardinal Health counter Talk
- 43:34Speaker 4: podcast wherever you get your podcasts.
- 43:36Speaker 3: See you on the next episode, and take care everyone.
- 43:39Speaker 1: Thank you.